Julian Symons

Rapt Therapeutics (United States) — United States

Medicine · Health Sciences

46h-index9.6kcitations163works4.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(36), Hepatitis B Virus Studies(27), HIV/AIDS drug development and treatment(13), Herpesvirus Infections and Treatments(13), Respiratory viral infections research(13)

Publications163 total

Structural basis for pan-coronavirus inhibition of 3CL protease
Structure·2026
Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor
Journal of Medicinal Chemistry·2025· 1 cited
THU-242 Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
Journal of Hepatology·2025
FRI-257 Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates
Journal of Hepatology·2025
FRI-450 ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice
Journal of Hepatology·2025
The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075
Journal of Medicinal Chemistry·2024· 21 cited
1341 Discovery and preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancer
Regular and Young Investigator Award Abstracts·2024Open Access
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH
Journal of Medicinal Chemistry·2024· 32 citedOpen Access
TOP-357 Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
Journal of Hepatology·2024
THU-198 In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Journal of Hepatology·2024
TOP-358-YI Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
Journal of Hepatology·2024
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
Antiviral Research·2024
Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
International Journal of Molecular Sciences·2023· 10 citedOpen Access
1382 Discovery of ALG-094103, a liver-targeted and orally bioavailable small molecule PD-L1 inhibitor for the treatment of liver cancer
Regular and Young Investigator Award Abstracts·2023Open Access
1381 Discovery of ALG-093989, a highly potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancers
Regular and Young Investigator Award Abstracts·2023Open Access
Novel non-HAP class A HBV capsid assembly modulators have distinct <i>in vitro</i> and <i>in vivo</i> profiles
Journal of Virology·2023· 8 citedOpen Access
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results
PLoS ONE·2023· 23 citedOpen Access
Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma
Journal of Hepatology·2023
A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice
Journal of Hepatology·2023· 1 cited
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
Journal of Hepatology·2023
page 1 of 9Next →

Frequent Co-authors

Geoffrey L. Smith(11), Gordon W. Duff(9), Lawrence M. Blatt(9), Leo Beigelman(8), Nick Cammack(8), Isabel Nájera(8), Sophie Le Pogam(7), Wen-Rong Jiang(7), David B. Smith(7), Antonio Alcamı́(6), Sushmita Chanda(6), Klaus Klumpp(6), Vincent Lévêque(6), Hyunsoon Kang(6), Jérôme Deval(6), N.C. Wood(5), Han Ma(5), Jérôme Deval(5), Sonal Rajyaguru(5), Samir Ali(5)